Safety of magnetic resonance imaging in patients with surgically implanted permanent epicardial leads.


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
08 2023
Historique:
received: 26 12 2022
revised: 28 03 2023
accepted: 09 04 2023
medline: 1 8 2023
pubmed: 20 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

Magnetic resonance imaging (MRI) safety in patients with an epicardial cardiac implantable electronic device (CIED) is uncertain. The purpose of this study was to assess the safety and adverse effects of MRI in patients who had surgically implanted epicardial CIED. Patients with surgically implanted CIEDs who underwent MRI with an appropriate cardiology-radiology collaborative protocol between January 2008 and January 2021 were prospectively studied in 2 clinical centers. All patients underwent close cardiac monitoring through MRI procedures. Outcomes were compared between the epicardial CIED group and the matched non-MRI-conditional transvenous CIED group. Twenty-nine consecutive patients with epicardial CIED (41.4% male; mean age 43 years) underwent 52 MRIs in 57 anatomic regions. Sixteen patients had a pacemaker, 9 had a cardiac defibrillator or cardiac resynchronization therapy-defibrillator, and 4 had no device generator. No significant adverse events occurred in the epicardial or transvenous CIED groups. Battery life, pacing, sensing thresholds, lead impedance, and cardiac biomarkers were not significantly changed, except 1 patient had a transient decrease in atrial lead sensing function. MRI of CIEDs with epicardially implanted leads does not represent a greater risk than transvenous CIEDs when performed with a multidisciplinary collaborative protocol centered on patient safety.

Sections du résumé

BACKGROUND
Magnetic resonance imaging (MRI) safety in patients with an epicardial cardiac implantable electronic device (CIED) is uncertain.
OBJECTIVE
The purpose of this study was to assess the safety and adverse effects of MRI in patients who had surgically implanted epicardial CIED.
METHODS
Patients with surgically implanted CIEDs who underwent MRI with an appropriate cardiology-radiology collaborative protocol between January 2008 and January 2021 were prospectively studied in 2 clinical centers. All patients underwent close cardiac monitoring through MRI procedures. Outcomes were compared between the epicardial CIED group and the matched non-MRI-conditional transvenous CIED group.
RESULTS
Twenty-nine consecutive patients with epicardial CIED (41.4% male; mean age 43 years) underwent 52 MRIs in 57 anatomic regions. Sixteen patients had a pacemaker, 9 had a cardiac defibrillator or cardiac resynchronization therapy-defibrillator, and 4 had no device generator. No significant adverse events occurred in the epicardial or transvenous CIED groups. Battery life, pacing, sensing thresholds, lead impedance, and cardiac biomarkers were not significantly changed, except 1 patient had a transient decrease in atrial lead sensing function.
CONCLUSION
MRI of CIEDs with epicardially implanted leads does not represent a greater risk than transvenous CIEDs when performed with a multidisciplinary collaborative protocol centered on patient safety.

Identifiants

pubmed: 37075957
pii: S1547-5271(23)02102-1
doi: 10.1016/j.hrthm.2023.04.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1111-1118

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Yue-Dong Ma (YD)

Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Robert E Watson (RE)

Department of Radiology, Mayo Clinic, Rochester, Minnesota.

Nora E Olson (NE)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Ulrika Birgersdotter-Green (U)

Department of Cardiovascular Medicine, University of California, San Diego Health System, San Diego, California.

Kavisha Patel (K)

Department of Cardiovascular Medicine, University of California, San Diego Health System, San Diego, California.

Siva K Mulpuru (SK)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Malini Madhavan (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Abhishek J Deshmukh (AJ)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Ammar M Killu (AM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Paul A Friedman (PA)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.

Yong-Mei Cha (YM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: ycha@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH